HUE053949T2 - N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok - Google Patents

N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Info

Publication number
HUE053949T2
HUE053949T2 HUE10739701A HUE10739701A HUE053949T2 HU E053949 T2 HUE053949 T2 HU E053949T2 HU E10739701 A HUE10739701 A HU E10739701A HU E10739701 A HUE10739701 A HU E10739701A HU E053949 T2 HUE053949 T2 HU E053949T2
Authority
HU
Hungary
Prior art keywords
protofibrils
oligomers
terminally truncated
antibodies selective
truncated amyloid
Prior art date
Application number
HUE10739701A
Other languages
English (en)
Hungarian (hu)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of HUE053949T2 publication Critical patent/HUE053949T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE10739701A 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok HUE053949T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
HUE053949T2 true HUE053949T2 (hu) 2021-08-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10739701A HUE053949T2 (hu) 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP3892633A1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CN101421303B (zh) 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
HRP20180230T8 (hr) 2010-02-26 2021-04-30 Bioarctic Neuroscience Ab Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija
SG192805A1 (en) 2011-03-16 2013-09-30 Probiodrug Ag Diagnostic antibody assay
MY184890A (en) 2014-07-10 2021-04-29 Bioarctic Neuroscience Ab Improved a? protofibril binding antibodies
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
EP3484918A1 (en) 2016-07-14 2019-05-22 BioArctic Neuroscience AB Brain delivery protein
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
JP7541505B2 (ja) 2018-07-24 2024-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病の治療及び予防方法
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
FI4172199T3 (fi) 2020-06-26 2025-08-12 Bioarctic Ab Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
US20250377367A1 (en) 2022-02-02 2025-12-11 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
KR20250134612A (ko) 2022-12-22 2025-09-11 바이오악틱 에이비 Abetape3에 결합하는 항체
US20250388664A1 (en) 2024-06-20 2025-12-25 Bioarctic Ab Bispecific binding molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
WO2001010900A2 (en) * 1999-08-04 2001-02-15 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en) * 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
EP2067789A1 (en) * 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EA016357B1 (ru) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
CN101421303B (zh) * 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
MY158903A (en) * 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
ES2709048T3 (es) * 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína

Also Published As

Publication number Publication date
JP2019218362A (ja) 2019-12-26
CA2765602A1 (en) 2011-01-06
US20120100129A1 (en) 2012-04-26
EP2448968A1 (en) 2012-05-09
CA2765602C (en) 2021-05-25
SI2448968T1 (sl) 2021-07-30
JP2012532094A (ja) 2012-12-13
EP3892633A1 (en) 2021-10-13
HRP20210611T1 (hr) 2021-05-28
PT2448968T (pt) 2021-04-30
AU2010267640B2 (en) 2015-03-05
JP6884025B2 (ja) 2021-06-09
ES2864049T3 (es) 2021-10-13
PL2448968T3 (pl) 2021-09-13
CY1124034T1 (el) 2022-05-27
SMT202100237T1 (it) 2021-05-07
EP2448968B1 (en) 2021-01-27
US20230295283A1 (en) 2023-09-21
JP2017197531A (ja) 2017-11-02
LT2448968T (lt) 2021-05-10
DK2448968T3 (da) 2021-04-12
AU2010267640A1 (en) 2012-01-19
WO2011001366A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
HUE053949T2 (hu) N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok
PT2406284T (pt) Anticorpos anti-bcma
EP2406399A4 (en) MIRAC PROTEINS
DOS2010000009S (es) Botella
DK2480734T3 (da) Skinnesystem
DOS2010000006S (es) Botella
EP2448809A4 (en) CHANNEL SYSTEM
UY3958Q (es) Botella
BRPI1008979A2 (pt) meio de fixação
ITPD20090053U1 (it) Paradordi per banchine
ES1071736Y (es) Botella
DE112010001522A5 (de) Mobile förderbrücke
DE112010001392A5 (de) Vibrator
ITCT20090003U1 (it) Telepass -2 per non udenti
TH93312B (th) ขวด
FR2951765B1 (fr) Paumelle pour persiennes
FI20090461A0 (fi) Määritysmenetelmä
FI20090460A0 (fi) Määritysmenetelmä
FI20096331A0 (fi) Antibodin käyttö
DOS2009000212S (es) Botella
DOS2009000147S (es) Botella
CR10687S (es) Viga bloque
TH93146B (th) ขวด
CN301360184S (zh)
UA19053S (uk) Пляшка